Fennec Pharmaceuticals (FENC) Current Deferred Revenue (2024 - 2025)
Fennec Pharmaceuticals (FENC) posted Current Deferred Revenue of $248000.0 for Q4 2025, little changed on a QoQ basis from $248000.0 in Q3 2025, and little changed year-over-year from $248000.0 in Q4 2024.
Fennec Pharmaceuticals (FENC) Current Deferred Revenue (2024 - 2025) Analysis & Trends
Fennec Pharmaceuticals' Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $248000.0 for Q4 2025.
- Quarterly Current Deferred Revenue changed 0.0% year-over-year to $248000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $248000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $248000.0, changed 0.0% from the prior year.
- Current Deferred Revenue was $248000.0 for Q4 2025 at Fennec Pharmaceuticals, roughly flat from $248000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $252000.0 in Q1 2024 and bottomed at $248000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Fennec Pharmaceuticals | 346.75 Mn | 309.97 Mn | 12.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 248,000.00 |
| Sep 30, 2025 | 248,000.00 |
| Jun 30, 2025 | 248,000.00 |
| Mar 31, 2025 | 248,000.00 |
| Dec 31, 2024 | 248,000.00 |
| Sep 30, 2024 | 248,000.00 |
| Jun 30, 2024 | 252,000.00 |
| Mar 31, 2024 | 252,000.00 |